Data / Drug companies / Viatris Specialty LLC
Viatris Specialty LLC: 79 products in the FDA NDC directory, labeler code 58151
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Viatris Specialty LLC (labeler code 58151) lists 79 products in the FDA National Drug Code Directory, covering 21 finished drugs by generic name. By type: 79 prescription drugs. Its main marketing category is new drug applications (NDA). The newest product started marketing on September 28, 2026.
The request: Watch Viatris Specialty LLC (FDA labeler code 58151): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 58151
- Products in commercial distribution
- 79
- Packages
- 101
- Finished drugs by generic name
- 21
- Prescription products
- 79
- Over the counter products
- 0
- Controlled substance products
- Schedule IV 6, Schedule V 12
- Flagged as original packager
- 60 of 60 products that carry the flag
- Started marketing in the last 12 months
- 15
- Products with a marketing end date set
- 6
- Earliest marketing start
- September 12, 2023
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| New drug applications (NDA) | 77 | 97.5% |
| Generic drugs (ANDA) | 2 | 2.5% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 79 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Pregabalin | 12 | 54 |
| Amlodipine and atorvastatin | 8 | 9 |
| Sildenafil citrate | 6 | 24 |
| Alprazolam | 6 | 37 |
| Gabapentin | 6 | 91 |
| Doxazosin | 4 | 28 |
| Ziprasidone | 4 | 7 |
| Sertraline hydrochloride | 4 | 55 |
| Atorvastatin calcium | 4 | 59 |
| Celecoxib | 4 | 63 |
| Amlodipine besylate | 3 | 49 |
| Nitroglycerin | 3 | 40 |
| Venlafaxine hydrochloride | 3 | 48 |
| Eplerenone | 2 | 12 |
| Doxazosin mesylate | 2 | 12 |
| Extended phenytoin sodium | 2 | 4 |
| Eletriptan hydrobromide | 2 | 11 |
| Phenytoin | 1 | 12 |
| Latanoprost | 1 | 15 |
| Tolterodine tartrate | 1 | 13 |
| Ziprasidone mesylate | 1 | 9 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, film coated | 24 | 30.4% |
| Capsule | 19 | 24.1% |
| Tablet | 16 | 20.3% |
| Tablet, film coated, extended release | 5 | 6.3% |
| Capsule, extended release | 5 | 6.3% |
| Solution | 2 | 2.5% |
| Tablet, extended release | 2 | 2.5% |
| Injection, solution | 1 | 1.3% |
| Suspension | 1 | 1.3% |
| Solution/ drops | 1 | 1.3% |
| Solution, concentrate | 1 | 1.3% |
| Powder, for suspension | 1 | 1.3% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Caduet | 58151-061 | Tablet, film coated | New drug applications (NDA) | September 28, 2026 |
| Caduet | 58151-060 | Tablet, film coated | New drug applications (NDA) | September 28, 2026 |
| Geodon | 58151-132 | Capsule | New drug applications (NDA) | September 16, 2026 |
| Cardura | 58151-077 | Tablet | New drug applications (NDA) | July 15, 2026 |
| Caduet | 58151-064 | Tablet, film coated | New drug applications (NDA) | June 24, 2026 |
| Revatio | 58151-402 | Tablet, film coated | New drug applications (NDA) | June 22, 2026 |
| Geodon | 58151-134 | Capsule | New drug applications (NDA) | April 15, 2026 |
| Neurontin | 58151-282 | Capsule | New drug applications (NDA) | April 9, 2026 |
| Caduet | 58151-067 | Tablet, film coated | New drug applications (NDA) | February 26, 2026 |
| Caduet | 58151-066 | Tablet, film coated | New drug applications (NDA) | February 26, 2026 |
| Caduet | 58151-065 | Tablet, film coated | New drug applications (NDA) | February 25, 2026 |
| Caduet | 58151-063 | Tablet, film coated | New drug applications (NDA) | February 25, 2026 |
| Caduet | 58151-062 | Tablet, film coated | New drug applications (NDA) | February 25, 2026 |
| Neurontin | 58151-290 | Solution | New drug applications (NDA) | January 14, 2026 |
| Cardura | 58151-076 | Tablet | New drug applications (NDA) | January 14, 2026 |
| Xanax | 58151-455 | Tablet | New drug applications (NDA) | October 29, 2025 |
| Xanax | 58151-452 | Tablet | New drug applications (NDA) | October 29, 2025 |
| Xanax | 58151-454 | Tablet | New drug applications (NDA) | October 2, 2025 |
| Neurontin | 58151-284 | Tablet, film coated | New drug applications (NDA) | October 1, 2025 |
| Neurontin | 58151-283 | Capsule | New drug applications (NDA) | October 1, 2025 |
| Neurontin | 58151-285 | Tablet, film coated | New drug applications (NDA) | September 19, 2025 |
| Geodon | 58151-137 | Injection, powder, lyophilized, for solution | New drug applications (NDA) | September 9, 2025 |
| Geodon | 58151-133 | Capsule | New drug applications (NDA) | September 9, 2025 |
| Geodon | 58151-131 | Capsule | New drug applications (NDA) | September 9, 2025 |
| Viagra | 58151-427 | Tablet, film coated | New drug applications (NDA) | August 5, 2025 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.